SEINE BIO · Research, evidence & your next steps
Mitochondrial science with a precise clinical focus.
SS-31, also known as elamipretide, has a defined place in the story of mitochondrial medicine. Explore the specialist evidence and understand why a specific disease indication matters when discussing broader energy or wellness goals.
Evidence for an approved medicine does not establish approval or equivalence of this catalog formulation.
How SS-31 works
Elamipretide interacts with cardiolipin in the inner mitochondrial membrane. Its clinical development focuses on mitochondrial function; the mechanism does not establish enhanced energy or longevity in otherwise healthy people.
Why it’s getting attention
Forzinity received FDA accelerated approval in 2025 to improve muscle strength in patients with Barth syndrome weighing at least 30 kg. Continued approval may depend on confirmation of clinical benefit. This catalog formulation is not established as Forzinity.
Protocol reference at a glance
Reference context, not your prescription. Reference example only: the Forzinity label for its specific Barth-syndrome population, not SEINE BIO directions.
| Stage | What to expect from the evidence |
|---|---|
| Routine reference dose | 40 mg subcutaneously once daily For the label’s specified patients; not a wellness dose. |
| Loading phase | No separate loading regimen stated in this reference Do not load to compensate for fatigue or a missed dose. |
| Maintenance / limits | Daily treatment with specialist monitoring Renal impairment can change labeled dosing; no validated anti-aging maximum or cycle. |
| Clinical reassessment | Monitor tolerability and disease-specific response Accelerated approval is not proof of broader longevity benefits. |
Presentation & administration
The approved reference medicine uses daily subcutaneous administration. Approval does not extend to a different SS-31 vial, cartridge, pen or nasal preparation.
Catalog presentation: Vial / Cartridge / Disposable Injection Pen. Listed strength options: 10 mg; 50 mg. One catalog unit is one selected presentation—not a box containing every pictured format. Total container content is not a personal dose, and an illustration does not verify an approved route or device.
Risks & common side effects
- Injection-site reactions and hypersensitivity are important reference-label risks. Persistent local reactions warrant review; breathing difficulty or facial swelling needs emergency care.
- Kidney function can affect reference dosing, so a fixed online dose is inappropriate. A separate formulation needs its own quality, stability and clinical review.
Tell your clinician about new or persistent symptoms and other medicines. Changes to treatment should be clinician-directed.
Other options worth discussing
For Barth syndrome, discuss approved care with a specialist. For fatigue or performance concerns, evaluate sleep, anemia, endocrine disease, medications and other causes rather than assuming mitochondrial treatment is indicated. “More established” does not mean risk-free or suitable for everyone; a clinician should compare benefits, contraindications and your preferences.
When to seek help
Do not treat fatigue as a confirmed mitochondrial disease; evaluation may reveal a more established and treatable cause.
Finished-product quality, concentration and route require verification. Review allergies, pregnancy, health conditions and other medicines with your clinician.
Do not wait for a portal reply in an emergency. Call 911 or seek emergency care for severe or rapidly worsening symptoms.
A few useful answers
Is SS-31 now approved for anti-aging?
No. Forzinity’s approval is specific to Barth syndrome and its labeled population.
Does this listing carry that approval?
No established equivalence or approval has been demonstrated for this catalog formulation.
Does clinician authorization guarantee access?
No. Clinical appropriateness, lawful availability and a verified finished formulation must each be established. An Rx setting, luxury image or research-series label does not create regulatory approval.
Research & references
General information, not a prescription or a guarantee of results. Research and reference-label schedules do not replace instructions for your exact prescribed product. Clinical suitability and lawful availability require separate confirmation.
Make your next step an informed one.
Share what you want to improve, what you have already tried, and the questions you have about SS-31. Your care team can help put the evidence and alternatives in context.
Sign-in may be required. This is not an emergency service or a guarantee that this product is available.
Product codes & historical records
Historical catalog reference
Source snapshot captured October 11, 2026. Historical catalog reference only; this draft is unavailable for purchase. Supplier prices, packaging, stock and reported test content describe the archived source entries, not a current SEINE BIO supply lot.
SS-31 — 50 mg per vial
Product Code: 2850
Original supplier title: 2850 (10*50mg)
| Supplier | Supplier |
|---|---|
| Supplier pack | 10 vials |
| Nominal content | 50 mg per vial |
| Source listed price (USD) | $285.00 per supplier pack |
| Source regular price (USD) | $310.00 per supplier pack |
| Source price per unit (USD) | $28.50 (arithmetic reference) |
| Batch shown on product page | 2026082850 |
| Source stock snapshot | 141 in stock — US warehouse |
| Source weight | 0.159 lbs |
| Source dimensions | 2.64 × 1.81 × 1.57 in |
Archived supplier description: No separate product description was displayed.
SS-31 — 50 mg per vial
Product Code: 2850-42
Original supplier title: 2850(10*50mg)Tested 42mg
| Supplier | Supplier |
|---|---|
| Supplier pack | 10 vials |
| Nominal content | 50 mg per vial |
| Source listed price (USD) | $250.00 per supplier pack |
| Source regular price (USD) | $280.00 per supplier pack |
| Source price per unit (USD) | $25.00 (arithmetic reference) |
| Batch shown on product page | 2026072850 |
| Source stock snapshot | 66 in stock — US warehouse |
| Source weight | 0.159 lbs |
| Source dimensions | 2.64 × 1.81 × 1.57 in |
Archived supplier description: No separate product description was displayed.
Source discrepancies / additional details: Nominal 50 mg; supplier title reports tested 42 mg.